Evidence map›Paper›PMID 35226308›Full record

ArticleInternational journal of hematology2022

Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies.

Tzu-Ting Chen, Ching-Chan Lin, Wen-Jyi Lo, Ching-Yun Hsieh, Ming-Yu Lien, Che-Hung Lin, Chen-Yuan Lin, Li-Yuan Bai, Chang-Fang Chiu, Su-Peng Yeh

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Tzu-Ting ChenDivision of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan.
Ching-Chan LinDivision of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan.
Wen-Jyi LoStem Cell Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Ching-Yun HsiehDivision of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan.
Ming-Yu LienDivision of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan.
Che-Hung LinDivision of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan.
Chen-Yuan LinDivision of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan.
Li-Yuan BaiDivision of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan.
Chang-Fang ChiuCancer Center, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan.
Su-Peng YehDivision of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan. supengyeh@gmail.com.ORCID http://orcid.org/0000-0001-6981-8677
China Medical University · TW

Funding

china medical university hospital DMR-107-019china medical university hospital NHRI-108A1-CACO-13191902
6 · The paper itself

Abstract

backgroundPost-transplant cyclophosphamide (PT-Cy) and calcineurin inhibitors used in peripheral blood haplo-identical stem cell transplantation (haploSCT) increase the risk of acute/chronic graft-versus-host disease (GVHD). Whether ATG/PT-Cy is feasible for Asian patients undergoing haploSCT is unclear, and an optimal strategy for GVHD prophylaxis is needed. MATERIALS AND

methodsWe retrospectively analyzed 61 hematologic malignancy patients who underwent peripheral blood haploSCT using ATG/PT-Cy from January 2013 to December 2018. We also compared the effects of ATG/PT-Cy (ATG group; n = 61) with historical data from patients who underwent haploSCT using sirolimus/PT-Cy (non-ATG group; n = 22).

resultsCumulative incidences of grades II-IV acute GVHD and moderate to severe chronic GVHD did not differ significantly. The ATG group had higher incidence of Epstein-Barr virus (EBV) reactivation, but neither group had post-transplant lymphoproliferative disorders. The ATG group also had a higher OS rate (2-year OS in ATG group vs. non-ATG group: 43.4% vs. 27.3%, respectively; P = 0.071).

conclusionATG/PT-Cy is an acceptable strategy for GVHD prophylaxis in Asian patients undergoing haploSCT.

Indexed as

Epstein-Barr Virus InfectionsGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell TransplantationAntilymphocyte SerumCyclophosphamideHerpesvirus 4, HumanHumansRetrospective StudiesTransplantation ConditioningAntilymphocyte SerumCyclophosphamideATGHaploidentical PBSCTSirolimus

Identifiers

PMID35226308
OpenAlexW4214738112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.